Dovitinib multi target TKI

CHIR-258 - CHIR258 - CHIR 258 - dovitinib - TKI-258 - TKI258 - TKI 258



Trial Studied treatment Control Patients Size Study type Results NCT

Renal-cell carcinoma (advanced) - multi target TKI in all type of patients

GOLDdovitinibsorafenib570 (284/286) NCT01223027



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons